Abstract: In one aspect, the present disclosure relates generally to a set acoustic adhesive composition having a storage modulus at 20° C. of at least 2.0 MPa over a frequency of 1-10 kHz, the set acoustic adhesive composition comprising: a continuous phase of a viscoelastic material present in an amount in the range of 60-95 wt % of the set adhesive composition; and dispersed in the continuous phase, a particulate polymer filler present in an amount in the range of 5-40 wt % of the set adhesive composition, wherein the particulate polymer filler has a storage modulus at 20° C. of at least 50 times a storage modulus at 20° C. of the continuous phase at 20° C., over a frequency of 1-10 kHz; and/or the viscoelastic material of the continuous phase has a glass transition temperature (Tg) no greater than 0° C., and the particulate polymer filler has a glass transition temperature (Tg) of at least 60° C.

Abstract: Exemplary nanoparticle and method for inducing photon avalanching using a nanoparticle can be provided. The nanoparticle can include, for example, at least 99% thulium doped nanocrystals of the nanoparticle. The nanoparticle can be composed of solely thulium. An atomic concentration of the thulium can be at least 8%. A near infrared excitation wavelength of the nanocrystals can be greater than about 1064 nm. The near infrared excitation wavelength can be between about 1400 nm to about 1490 nm. A passivated shell(s) can be included which can surround the nanocrystals.

Abstract: The present invention provides a method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) comprising: providing a starting population of cells; depleting said starting population of cells which express a target antigen; and introducing into a cell in the depleted starting population a nucleic acid sequence which encodes a CAR or transgenic TCR against the target antigen. The present invention also provides genetically modified cells, pharmaceutical compositions and pharmaceutical compositions for use in the treatment and/or prevention of disease.

Abstract: The present invention provides a method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) comprising: providing a starting population of cells; depleting said starting population of cells which express a target antigen; and introducing into a cell in the depleted starting population a nucleic acid sequence which encodes a CAR or transgenic TCR against the target antigen. The present invention also provides genetically modified cells, pharmaceutical compositions and pharmaceutical compositions for use in the treatment and/or prevention of disease.